About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Liver Diseases group is a referent at the local, national and international level in research, and is one of the most active groups in clinical research at VHIR. The group's prominent involvement in clinical trials is a clear indication of our professionals' commitment to ensuring that patients have access to state-of-the-art therapies. Our participation and collaboration in international projects and consortiums are also a fundamental characteristic of the group. The main objective of the group is to become one of the best translational research groups in liver diseases. It is essential to be able to apply all the findings of basic research to clinical research to improve the health of patients with liver disease.
IP: Maria Buti Ferret Collaborators: Maria del Mar Riveiro Barciela Funding agency: GILEAD SCIENCES SLU Funding: 48763 Reference: GLD21_00139 Duration: 30/06/2022 - 30/06/2024
PMID: 37884354 Journal: GUT Year: 2023 Reference: Gut. 2023 Oct 26:gutjnl-2023-329923. doi: 10.1136/gutjnl-2023-329923. Impact factor: Publication type: Paper in international publication Authors: Abraldes, Juan G; Agueras, Cajal; Alessandria, Carlo; Allegretti, Andrew S; Alonso, Sonia; Asrani, Sumeet K; Beuers, Ulrich; Campion, Daniela; Caraceni, Paolo; de Wit, Koos et al. DOI: 10.1136/gutjnl-2023-329923
PMID: 37893239 Journal: Biomedicines Year: 2023 Reference: Biomedicines. 2023 Oct 23;11(10):2867. doi: 10.3390/biomedicines11102867. Impact factor: Publication type: Paper in international publication Authors: Aban, M; Abraldes, Juan G; Alegre-Martin, Jose; Alessandria, Carlo; Allegretti, Andrew S; Alonso, Sonia; Andrade, R; Angeli, P; Asrani, Sumeet K; Avitabile, E et al. DOI: 10.3390/biomedicines11102867
PMID: 37896223 Journal: Pharmaceutics Year: 2023 Reference: Pharmaceutics. 2023 Oct 14;15(10):2463. doi: 10.3390/pharmaceutics15102463. Impact factor: Publication type: Paper in international publication Authors: Abasolo, Ibane; Agarwal, Neeraj; Andrade, Fernanda; Azad, Arun A; Chakrabarti, Jayeta; Chen, Hsiang-Chun; Fizazi, Karim; Genesca, Joan; Gil, Mar; Hide, Diana et al. DOI: 10.3390/pharmaceutics15102463
PMID: 37892611 Journal: Journal of Clinical Medicine Year: 2023 Reference: J Clin Med. 2023 Oct 11;12(20):6471. doi: 10.3390/jcm12206471. Impact factor: Publication type: Paper in international publication Authors: Abe, Hiroshi; Ahn, Sang Bong; Aldea-Perona, Ana; An, Jihyun; Arai, Taeang; Atsukawa, Masanori; Avendano-Sola, Cristina; Blasco Quilez, Maria Rosario; Bonilla-Toyos, Elvira; Bosch Ferrer, Montserrat et al. DOI: 10.3390/jcm12206471
PMID: 35487453 Journal: Clinical Gastroenterology and Hepatology Year: 2022 Reference: Clin Gastroenterol Hepatol. 2022 Apr 26. pii: S1542-3565(22)00403-7. doi: 10.1016/j.cgh.2022.03.050. Impact factor: 11.382 Publication type: Paper in international publication Authors: Riveiro-Barciela, Mar, Barreira-Diaz, Ana, Callejo-Perez, Ana, Munoz-Couselo, Eva, Diaz-Mejia, Nely, Diaz-Gonzalez, Alvaro, Londono, Maria-Carlota, Salcedo, Maria-Teresa, Buti, Maria et al. DOI: 10.1016/j.cgh.2022.03.050
PMID: 35453934 Journal: Diagnostics Year: 2022 Reference: Diagnostics (Basel). 2022 Apr 1;12(4). pii: diagnostics12040886. doi: 10.3390/diagnostics12040886. Impact factor: 3.706 Publication type: Paper in international publication Authors: Gabriel-Medina, Pablo, Diaz-Troyano, Noelia, Barquin-DelPino, Raquel, Castillo-Ribelles, Laura, Esteban, Angels, Hernandez-Gonzalez, Manuel, Ferrer-Costa, Roser, Pumarola, Tomas, Rodriguez-Frias, Francisco, Klammer, Martin et al. DOI: 10.3390/diagnostics12040886
PMID: 34964311 Journal: Hepatology Communications Year: 2022 Reference: Hepatol Commun. 2022 May;6(5):1100-1112. doi: 10.1002/hep4.1881. Epub 2021 Dec 28. Impact factor: 5.073 Publication type: Paper in international publication Authors: Esnault, V, Pose, Elisa, Sola, Elsa, Lozano, Juan J, Juanola, Adria, Sidorova, Julia, Zaccherini, Giacomo, Giovo, I, Roux, O, Simon-Talero, M et al. DOI: 10.1002/hep4.1881
PMID: 34877666 Journal: VOX SANGUINIS Year: 2022 Reference: Vox Sang. 2022 Apr;117(4):626-627. doi: 10.1111/vox.13229. Epub 2021 Dec 8. Impact factor: 2.144 Publication type: Letter or abstract Authors: Sauleda, Silvia, Piron, Maria, Bes, Marta, Martinez-Llonch, Nuria, Puig, Lluis et al. DOI: 10.1111/vox.13229
PMID: 28051797 Journal: Annals of Hepatology Year: 2017 Reference: Ann Hepatol. 2017 Jan-Feb 2017;16(1):86-93. doi: 10.5604/16652681.1226819. Impact factor: 1.678 Publication type: Paper in international publication Authors: Salcedo, Teresa, Esteban, Juan Ignacio, Esteban-Mur, Rafael, Charco, Ramon, Rodriguez-Frias, Francisco, Len, Oscar, Crespo, Manel, Castells, Lluis, Llaneras, Jordi, Campos-Varela, Isabel et al. DOI: 10.5604/16652681.1226819
Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.
The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.
The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.
Des de Vall d'Hebron estem buscant 200 persones voluntàries sanes d'entre 18 i 30 anys per a participar en un estudi sobre els patrons de consum habitual de l'alcohol en població jove, en el marc del projecte StopALD.
